- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Di | eXoZymes to Host Second Quarter 2026 Update Conference Call on Thursday, August 20, 2026 | 212 | ACCESS Newswire | Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals and novel medicines - announced the plan to host a webinar... ► Artikel lesen | |
| EXOZYMES Aktie jetzt für 0€ handeln | |||||
| 23.07. | eXoZymes Selected for DoE's Genesis Mission to Advance AI-Powered Digital Twins for Cell-Free Biomanufacturing | 442 | ACCESS Newswire | Company to collaborate with Lawrence Berkeley National Laboratory on AI-enabled digital twins designed to accelerate optimization of enzyme-driven manufacturing processes.The 9-month project awarded... ► Artikel lesen | |
| 26.06. | eXoZymes erhält 2 Millionen US-Dollar vom NIH zur Weiterentwicklung von Cannabinoid-Analoga für die Arzneimittelforschung | 1 | Bionity.com | ||
| 26.06. | EXOZYMES INC. - 8-K, Current Report | - | SEC Filings | ||
| 24.06. | Cannabinoid-Forschung: eXoZymes sichert sich NIH-Zuschuss über 2 Millionen US-Dollar | 1 | Investing.com Deutsch | ||
| 24.06. | exoZymes receives $2M NIH grant for cannabinoid research | 1 | Investing.com | ||
| 24.06. | eXoZymes awarded $2M NIH Grant to advance cannabinoid analogs for drug discovery | 2 | Seeking Alpha | ||
| 24.06. | eXoZymes Awarded $2 Million NIH Grant to Advance Cannabinoid Analogs for Drug Discovery | 397 | ACCESS Newswire | Award allows eXoZymes to expand its portfolio of proprietary new-to-nature molecules and potential future pharmaceutical assets and validates the Company's ability to make rare cannabinoids and new... ► Artikel lesen | |
| 17.06. | EXOZYMES INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.06. | eXoZymes schließt Kapitalerhöhung über 5,95 Mio. US-Dollar ab | 2 | Investing.com Deutsch | ||
| 17.06. | eXoZymes closes $5.95M public offering of stock and warrants | 1 | Investing.com | ||
| 17.06. | eXoZymes Inc. Announces Closing of $6 Million Public Offering | 460 | ACCESS Newswire | LOS ANGELES, CA / ACCESS Newswire / June 17, 2026 / eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes" or "Company"), a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals... ► Artikel lesen | |
| 08.06. | EXOZYMES INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.06. | eXoZymes prices $5.33M public offering of stock and warrants | 3 | Seeking Alpha | ||
| 08.06. | eXoZymes Inc. Announces Pricing of Public Offering of Common Stock and Warrants | 396 | ACCESS Newswire | LOS ANGELES, CA / ACCESS Newswire / June 8, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes" or "Company") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into valuable nutraceuticals... ► Artikel lesen | |
| 14.05. | EXOZYMES INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 07.05. | eXoZymes Announces Graduation from Shell GameChanger Accelerator Powered by NLR Program | 550 | ACCESS Newswire | LOS ANGELES, CA / ACCESS Newswire / May 7, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transform abundant feedstock into nutraceuticals, novel medicines... ► Artikel lesen | |
| 07.05. | EXOZYMES INC. - 8-K, Current Report | 2 | SEC Filings | ||
| 10.04. | EXOZYMES INC. - 8-K, Current Report | - | SEC Filings | ||
| 10.04. | eXoZymes CCO, Damien Perriman, Outlines NCTx Strategy and the Commercial Path for Cell-Free Biomanufacturing on Grow Everything Podcast | 851 | ACCESS Newswire | LOS ANGELES, CA / ACCESS Newswire / April 10, 2026 / Today, eXoZymes Inc. (NASDAQ:EXOZ) ("eXoZymes") - a pioneer of AI-enhanced enzymes that transforms abundant feedstock into valuable nutraceuticals... ► Artikel lesen |
1 2 Weiter >>
36 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PRAXIS PRECISION MEDICINES | 370,68 | +1,01 % | Praxis Precision Medicines, Inc. - 10-Q, Quarterly Report | ||
| QIAGEN | 37,075 | -3,58 % | Ihre wichtigsten Termine: Frische Zahlen von Ebay, Eli Lill, Allstate, Infineon, Novo Nordisk, Walt Disney | Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Untermehmenstermine 06:45 Uhr, Deutschland: Basler... ► Artikel lesen | |
| RELAY THERAPEUTICS | 19,990 | +0,25 % | Relay Therapeutics, Inc.: Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates | Selected zovegalisib plus atirmociclib as go-forward triplet regimen for 1L breast cancer; Phase 3 1L trial in endocrine- sensitive patients expected to initiate in early 2027, subject to regulatory... ► Artikel lesen | |
| COGENT BIOSCIENCES | 38,710 | -6,79 % | Cogent Biosciences, Inc. - 10-Q, Quarterly Report | ||
| MOONLAKE IMMUNOTHERAPEUTICS | 16,590 | -4,27 % | MoonLake Immunotherapeutics AG: MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial | Phase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokimabThe primary endpoint of ACR50 was met with a high response of 42.1% for sonelokimab's 60 mg with... ► Artikel lesen | |
| CG ONCOLOGY | 77,04 | +0,63 % | CG Oncology Inc.: CG Oncology Reports Second Quarter 2026 Financial Results and Provides Business Updates | PIVOT-006 Phase 3 topline data evaluating cretostimogene monotherapy as an adjuvant therapy in intermediate-risk NMIBC anticipated in the near-termBLA completion for HR BCG-unresponsive NMIBC expected... ► Artikel lesen | |
| VERA THERAPEUTICS | 30,320 | -3,99 % | Vera Therapeutics GAAP EPS of -$1.52 beats by $0.04 | ||
| APOGEE THERAPEUTICS | 134,71 | +0,04 % | Apogee Therapeutics: Apogee Reports Second Quarter 2026 Financial Results and Recent Corporate and Pipeline Updates | AbbVie to acquire Apogee for $135.11 per share in cash for total equity value of approximately $10.9 billion, positioning differentiated immunology portfolio to reach more patients worldwide Positive... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 15,110 | +1,61 % | H.C. Wainwright reiterates Neutral stock rating on Summit Therapeutics | ||
| TANGO THERAPEUTICS | 26,320 | -4,88 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| ERASCA | 18,310 | +1,05 % | Erasca, Inc. - 8-K, Current Report | ||
| ENLIVEN THERAPEUTICS | 58,76 | -1,11 % | Guggenheim lowers Enliven Therapeutics stock price target to $78 | ||
| PYXIS ONCOLOGY | 2,810 | -26,63 % | Pyxis Oncology Announces Up to $114 Million Private Placement Financing to Advance MICVO Through Key Clinical Milestones | Expected to extend cash runway into the second quarter of 2027, supporting additional follow-up for 2L+ R/M HNSCC patients treated with MICVO at or below a dose cap Company now expects updated Phase... ► Artikel lesen | |
| SIONNA THERAPEUTICS | 5,100 | -90,01 % | Sionna Therapeutics, Inc.: Sionna Therapeutics Reports Topline Data from Two Development Programs in Cystic Fibrosis and Provides Corporate Update | SION-719 Phase 2a proof-of-concept trial did not achieve key activity endpoint of sweat chloride reduction when added to standard of care; Company is not advancing SION-719 as an add-on to standard... ► Artikel lesen | |
| BICARA THERAPEUTICS | 23,800 | -14,17 % | Bicara Therapeutics Inc.: Bicara Therapeutics Reports Second Quarter 2026 Progress and Announces Strategic Leadership Transitions Marking Next Era of Execution and Growth | President & Chief Operating Officer Ryan Cohlhepp, Pharm.D. appointed President & Chief Executive Officer effective January 2027 Claire Mazumdar, Ph.D., MBA to transition to Vice Chair of the Board... ► Artikel lesen |
Das Unternehmen EXOZYMES INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 5,980 Euro und damit +15,22 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu EXOZYMES INC finden Sie auf Wallstreet Online.